This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Compelling Preclinical Breast Cancer Results
Race Oncology Limited (ASX: RAC) is pleased to share the final results of our collaborative preclinical research program with the eminent cancer researcher, Associate Professor Nikki Verrills of The University of Newcastle and Hunter Medical Research Institute. The aim of this research program was to identify combinations of existing breast cancer drugs which when paired…
-
Positive Early Preclinical Ovarian Cancer Results
Race Oncology Limited (ASX: RAC) is pleased to share further interim results of our continuing collaborative preclinical research program with The University of Newcastle. Eminent cancer researcher, Associate Professor Nikki Verrills of the Hunter Medical Research Institute is leading the project. The aim of this recent preclinical research program is to explore Bisantrene efficacy in…
-
MST Access initiates coverage of Race Oncology
MST Access has initiated coverage of Race Oncology with a current $4.88 per share valuation. The full report can be downloaded below.
-
Mary Harney appointed Non-Executive Director of Race
Race Oncology Limited (Race or the Company) (ASX: RAC) is pleased to announce that Ms Mary Harney has been appointed Non-Executive Director. An accomplished NED and Chief Executive, Ms Harney brings deep understanding of academic and applied life science research, in addition to biopharmaceutical regulatory affairs and commercialisation capabiliMs Harney is the director of specialist…
-
Race Oncology’s 2020 AGM
Race Oncology Limited (ASX: RAC) is pleased to release an extended version of the presentation from our 2020 Annual General Meeting (AGM). Race’s Managing Director and CEO, Mr Phil Lynch commented, “At the time we released our updated Three Pillar strategy at our AGM, we committed to making available a video presentation to those shareholders…
-
‘Three Pillar’ Strategic Update
Race Oncology is pleased to release our updated strategic plan for the clinical advancement of Bisantrene at our 2020 AGM. The recent identification of Bisantrene as a potent inhibitor of the Fat and obesity associated (FTO) protein, together with the outstanding results from the Sheba Medical Centre Phase II trial of Bisantrene in R/R acute…
-
Impressive Preclinical Bisantrene Breast Cancer Results
Race Oncology Limited (ASX: RAC) is pleased to share results of the collaborative preclinical research program between Race and The University of Newcastle. Eminent cancer researcher, Associate Professor Nikki Verrills of the Hunter Medical Research Institute is leading the project. The aim of this research program is to identify combinations of current breast cancer drugs…
-
Phase 2 Bisantrene trial data published in European Journal of Haematology
10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba Medical Centre has been published. This open label, single agent trial, led by Professor Arnon…
-
Phase II Bisantrene trial data to be presented at ASH 2020
5 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba Medical Centre has been accepted for presentation at the American Society for Haematology 2020 Conference…